MedPath

ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

Early Phase 1
Conditions
Hepatocellular Carcinoma
Liver Neoplasms
Liver Cancer
Metastatic Liver Cancer
Registration Number
NCT03965546
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Brief Summary

The purpose of this study is to evaluate the efficacy and safety of ET 140202 -T cell combined With TAE or Sorafenib in the treatment of liver cancer

Detailed Description

The molecular target for ET140202-T cells is HLA-A02 complexed with a HLA-A02-restricted peptide of alpha fetoprotein (AFP), which is expressed on 60-80 percent of hepatocellular carcinoma (HCC). This clinical study evaluates the safety and pharmacokinetics of ET140202-T cells with TAE or Sorafenib in patients with HCC who have no available curative therapeutic options and a poor overall prognosis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
27
Inclusion Criteria
  • AFP-expressing HCC and serum AFP >10 x ULN

  • Abandon or failure in first or second line treatment

  • Molecular HLA class I typing confirms participant carries at least one HLA-A02 allele

  • Child-Pugh score of A or B, ECOG 0-2, Life expectancy > 6 months

  • Measurable disease as defined by: at least 1 liver lesion that can be accurately and serially measured.

  • Negative serum pregnancy test for women with childbearing potential

  • Adequate organ function as defined below:

    1. A pretreatment measured creatinine clearance (absolute value) of ≥50 ml/minute.
    2. Patients must have a serum direct bilirubin ≤3 x ULN, ALT and AST ≤5 x ULN.
    3. Ejection Fraction measured by echocardiogram or MUGA >50% (evaluation done within 6 weeks of screening does not need to be repeated)
    4. DLCO or FEV1 >45% predicted
    5. Absolute neutrophil count (ANC) ≥ 1500/mm3 (10^9/L), Platelet count ≥ 50,000/mm3 (10^9/L)
    6. INR ≤1.5 x ULN
    7. Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
  • Patients with decompensated cirrhosis: Child-Pugh Score C
  • Patients with tumor infiltration in the portal vein, hepatic veins or inferior vena cava that completely blocks circulation in liver.
  • Patients with an organ transplantation history
  • Patients with dependence on corticosteroids
  • Patients with active autoimmune diseases requiring systemic immunosuppressive therapy
  • Patients who are currently receiving or received within past 30 days anti-cancer therapy, local treatments for liver tumors (radiotherapy, embolism, ablation) or liver surgery
  • Patients currently receiving other investigational treatments (biotherapy, chemotherapy, or radiotherapy)
  • Participants with other active malignancies (except non-melanoma skin cancer and cervical cancer) within two years. Patients with a history of successfully-treated tumors with no sign of recurrence in the last two years may be enrolled.
  • Patients with other uncontrolled diseases, such as active infections Acute or chronic active hepatitis B or hepatitis C.
  • Women who are pregnant or breast-feed
  • HIV-infection

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Frequency of ARTEMIS T cell treatment-related adverse events28 days up to 2 years

Include but not limited to: Fever, chills, nausea, vomiting, jaundice and other gastrointestinal symptoms; Fatigue, hypotension, respiratory distress; Tumor lysis syndrome; Cytokine release syndrome; Neutropenia, thrombocytopenia; Liver and kidney dysfunction. Assessed at all visits.

Secondary Outcome Measures
NameTimeMethod
IL-6 serum levels4-8 weeks

Amount change compared to the baseline

Overall survival(OS)at 2 years

overall survival(OS)at 2 years

IL-2 serum levels4-8 weeks

Amount change compared to the baseline

IL-10 serum levels4-8 weeks

Amount change compared to the baseline

Rate of disease response by RECIST at non-liver sites2 years

Response rates will be estimated as the percent of patients with objective response (OR), complete remission (CR), partial response (PR), stable disease (SD), no response (NR), overall survival (OS).

Median Survival(MS)at 4 months, 1 year, 2 years

Median Survival(MS)at 4 months, 1 year and 2 years

AFP serum levels2 years

Percent change compared to the baseline

Alpha-fetoprotein (AFP) expression in tumors4-8 weeks

Percent of AFP-positive cells in randomly selected fields in tumor biopsies.

Progression free survival (PFS)at 4 months, 1 year, 2 years

Progression free survival (PFS) at 4 months, 1 year and 2 years

Number of ET140202-T cells in peripheral blood2 years

Number of ET140202-T cells in peripheral blood will be presented as Time to peak, Time to baseline level

TNF-α serum levels4-8 weeks

Amount change compared to the baseline

IFN-γ serum levels4-8 weeks

Amount change compared to the baseline

Rate of disease response by RECIST in the liver2 years

Response rates will be estimated as the percent of patients with objective response (OR),which was defined as any of complete remission (CR), partial response (PR) at 2 years.

Trial Locations

Locations (1)

The First Affiliated Hospital of Xi'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

The First Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Yun Wang
Contact
86-18681869114
foolishyun@126.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.